FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

<b>STATEMENT</b>	<b>OF CHANGES</b>	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Riley Wayne Joseph</u>			$ \underline{\mathbf{v}} $	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [ VRTX ]						(Che	Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner				
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED				3.	3. Date of Earliest Transaction (Month/Day/Year) 06/01/2014						Officer below)	(give title	Other (s below)	pecify	
50 NORTHERN AVENUE  (Street)  BOSTON MA 02210  (City) (State) (Zip)			4.	If Ame	ndment, I	Date (	of Original File	d (Month/Day	//Year)	6. In Line	Form fil	oint/Group Filin	orting Persor	.	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date			Transaction ate Ionth/Day/Y	Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 3, 5) Disposed Of (D) (Instr. 3, 6)		d (A) or r. 3, 4 and Price	Securitie Beneficia Owned F Reported Transacti	5. Amount of Securities Form Beneficially (D) of Owned Following Reported Transaction(s) (Instr. 3 and 4)		7. Nature of ndirect Beneficial Ownership Instr. 4)					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security  (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  (Instr. 3)  2. Conversion Date Execution Date (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)		Code (	1. Transaction Code (Instr. 3)  3)  5. Number of Operivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and An of Securities Underlying Derivative Sec (Instr. 3 and 4)		es g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option	\$72.14	06/01/2014		A		20,000		06/01/2014 <sup>(1)</sup>	05/31/2024	Common Stock	20,000	\$0.00	20,000	D	

Explanation of Responses:

1. Fully vested.

Remarks:

Kenneth L. Horton, Attorney-

06/03/2014

<u>In-Fact</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.